Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030- Product Image

Sale

Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030

Report
184 Pages
March 2024
Region: Global
360iResearch™
ID: 4829825

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Pulmonary Drugs Market size was estimated at USD 72.73 billion in 2022, USD 79.35 billion in 2023, and is expected to grow at a CAGR of 8.16% to reach USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pulmonary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Anti-Cholinergic Agents
- Anti-Leukotrienes
- Antihistamines
- Beta-2 Agonists
- Combination Drugs
- Monoclonal Antibodies
- Oral & Inhaled Corticosteroids
Indication
- Allergic Rhinitis
- Asthma
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Pulmonary Arterial Hypertension
Drug Type
- Generic Drugs
- Prescription Drugs
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
End-User
- Homecare
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Pulmonary Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pulmonary Drugs Market?
What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?
What is the market share of the leading vendors in the Pulmonary Drugs Market?
Which modes and strategic moves are suitable for entering the Pulmonary Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Pulmonary Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
5.1.2. Restraints
5.1.2.1. Increasing recall of drugs used for pulmonary conditions
5.1.3. Opportunities
5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
5.1.4. Challenges
5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
5.2. Market Segmentation Analysis
5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
5.3. Market Trend Analysis
5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government’s financial support for drug commercialization
5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Pulmonary Drugs Market, by Drug Class

6.1. Introduction
6.2. Anti-Cholinergic Agents
6.3. Anti-Leukotrienes
6.4. Antihistamines
6.5. Beta-2 Agonists
6.6. Combination Drugs
6.7. Monoclonal Antibodies
6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

7.1. Introduction
7.2. Allergic Rhinitis
7.3. Asthma
7.4. Chronic Obstructive Pulmonary Disease
7.5. Cystic Fibrosis
7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

8.1. Introduction
8.2. Generic Drugs
8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Agreement, Collaboration, & Partnership
14.3.1.1. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
14.3.1.2. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
14.3.1.3. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy
14.3.2. New Product Launch & Enhancement
14.3.2.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
14.3.2.2. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
14.3.3. Investment & Funding
14.3.3.1. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
14.3.3.2. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
14.3.3.3. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
14.3.4.2. U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
14.3.4.3. US FDA Approves GSK’s Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
14.3.4.4. AstraZeneca Launches New Asthma Medication Called Airsupra

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. AbbVie Inc.
15.1.3. Amgen Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bayer AG
15.1.6. Boehringer Ingelheim International GmbH
15.1.7. Bristol Myers Squibb Company
15.1.8. Chiesi Farmaceutici S.p.A
15.1.9. Cipla Ltd.
15.1.10. Dr. Reddy's Laboratories Ltd.
15.1.11. F. Hoffmann-La Roche AG
15.1.12. Gilead Sciences, Inc.
15.1.13. GlaxoSmithKline PLC
15.1.14. Grifols, S.A.
15.1.15. Icosavax, Inc.
15.1.16. Johnson & Johnson Services, Inc.
15.1.17. Lung Therapeutics Inc.
15.1.18. Lupin Pharmaceuticals, Inc.
15.1.19. Mallinckrodt PLC
15.1.20. Merck & Co., Inc.
15.1.21. Novartis AG
15.1.22. Pfizer Inc.
15.1.23. Pieris Pharmaceuticals, Inc.
15.1.24. Sanofi S.A
15.1.25. Sumitomo Pharma Co., Ltd.
15.1.26. Sun Pharmaceutical Industries Ltd.
15.1.27. Teva Pharmaceutical Industries Ltd.
15.1.28. United Therapeutics Corporation
15.1.29. Verona Pharma PLC
15.1.30. Vertex Pharmaceuticals Incorporated
15.1.31. Viatris Inc.
15.1.32. Wellona Pharma
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PULMONARY DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. PULMONARY DRUGS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. PULMONARY DRUGS MARKET DYNAMICS
FIGURE 7. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 8. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 10. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
FIGURE 12. PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 14. PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. PULMONARY DRUGS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 16. PULMONARY DRUGS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 14. PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 20. PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NORWAY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. POLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. POLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. POLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. QATAR PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. QATAR PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. SPAIN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. TURKEY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 240. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 241. PULMONARY DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Company
Chiesi Farmaceutici S.p.A
Cipla Ltd.
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Grifols, S.A.
Icosavax, Inc.
Johnson & Johnson Services, Inc.
Lung Therapeutics Inc.
Lupin Pharmaceuticals, Inc.
Mallinckrodt PLC
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Pieris Pharmaceuticals, Inc.
Sanofi S.A
Sumitomo Pharma Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Verona Pharma PLC
Vertex Pharmaceuticals Incorporated
Viatris Inc.
Wellona Pharma

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	184
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 79.35 Billion
Forecasted Market Value ( USD ) by 2030	$ 136.27 Billion
Compound Annual Growth Rate	8.1%
Regions Covered	Global
No. of Companies Mentioned	32

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,802GBP €3624EUR$3,749USD£3,113GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,549GBP €4591EUR$4,749USD£3,944GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,297GBP €5558EUR$5,749USD£4,774GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,044GBP €6525EUR$6,749USD£5,605GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7613EUR$7,874USD£6,539GBP €8458EUR$8,749USD£7,265GBP

Regional Insights

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Pulmonary Drug Delivery Devices Market by Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer), Application (Asthma, COPD, Cystic Fibrosis), Distribution Channel - Forecast 2024-2030

Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030

Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Chronic Obstructive Pulmonary Disease (COPD) Treatment: Global Strategic Business Report

Pulmonary Drug Delivery Market Report: Trends, Forecast and Competitive Analysis to 2030

About the Pulmonary Drug Market